Search Results

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.

Eli Lilly’s new research and development facility in Boston’s Seaport district will focus on DNA- and RNA-based therapies, as well as other priority areas such as diabetes and obesity.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

Boston Pharmaceuticals today announced the appointment of Margaret Koziel, M.D., as Chief Medical Officer (CMO). Juan Carlos Lopez-Talavera, M.D., Ph.D., who has served as acting CMO since December 2023, will move to an advisory role to Dr. Koziel and the Boston Pharmaceuticals team as the company advances its promising late-stage candidate BOS-580.

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.

Boston Pharmaceuticals has today named Dr. Elias Zerhouni as the new Chair of its Board of Directors, with Stefan Meister standing down from the Board after six years to focus on his ongoing roles elsewhere.

Novo Holdings, a leading life science investor, announced that its Boston office has been named a 2024 Best Place to Work by the Boston Business Journal.

An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.